ProCE Banner Activity

How to Switch ART in Virologically Suppressed Patients With Incomplete Resistance Histories

Conference Coverage
Clinical Thought
Here’s my take on which clinical data and patient parameters should be considered before making an ART switch in the context of virologic suppression.

Released: January 23, 2020

Expiration: January 21, 2021

No longer available for credit.

Share

Faculty

José R. Arribas

José R. Arribas, MD

Professor of Medicine
Department of Medicine
Autónoma University School of Medicine
Head, Infectious Diseases Unit
Department of Internal Medicine
Hospital La Paz
Madrid, Spain

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

ViiV Healthcare

Faculty Disclosure

Primary Author

José R. Arribas, MD

Professor of Medicine
Department of Medicine
Autónoma University School of Medicine
Head, Infectious Diseases Unit
Department of Internal Medicine
Hospital La Paz
Madrid, Spain

José R. Arribas, MD, has disclosed that he has received consulting fees from Aelix, Gilead Sciences, Janssen, Merck, Teva, and ViiV Healthcare and funds for research support from Gilead Sciences, Merck, and ViiV Healthcare.